Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges
Merck cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals.
Overview
Merck cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals.
Source
Originally published at www.cnbc.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.